Lupin has received final approval for its Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Concordia Pharmaceuticals Inc.'s Kapvay Extended-Release Tablets 0.1 mg.
Lupin's Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg is the AB rated generic equivalent of Concordia Pharmaceuticals Inc.'s Kapvay Extended-Release Tablets 0.1 mg. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications. As per IMS MAT Jun 2017, Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg had annual sales of around $66 million in the US.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
